E. Eigendorff
European Neuroendocrine Tumor Society · 23 works · 1,965 citations · h-index 10
Top works
- Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer
- LBA56 Overall survival in the KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small-cell lung cancer (NSCLC)
- Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial
- Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial
- 11β-Hydroxysteroid Dehydrogenase Types 1 and 2: An Important Pharmacokinetic Determinant for the Activity of Synthetic Mineralo- and Glucocorticoids
- KEYNOTE-671: Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC.
- Pharmacodynamics and Pharmacokinetics of Synthetic Mineralocorticoids and Glucocorticoids: Receptor Transactivation and Prereceptor Metabolism by 11β-hydroxysteroid-dehydrogenases
- 1235TiP Perioperative pembrolizumab + platinum-based chemotherapy for resectable locally advanced non-small cell lung cancer: The phase III KEYNOTE-671 study
- OA01.03 Association of Pathologic Regression with EFS in the KEYNOTE-671 Study of Perioperative Pembrolizumab for Early-Stage NSCLC
- Enhanced 11beta-hydroxysteroid dehydrogenase type 1 activity in stress adaptation in the guinea pig
- Health-related quality of life (HRQoL) outcomes from the randomized, double-blind phase 3 KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small-cell lung cancer (NSCLC).
- In Vivo Activity of 11β-Hydroxysteroid Dehydrogenase Type 1 in Man: Effects of Prednisolone and Chenodesoxycholic Acid
- Progrediente Niereninsuffizienz und Proteinurie bei einem 74-jährigen Patienten
- 223MO Five-year outcomes of participants with pathological complete response (pCR) enrolled in the KEYNOTE-671 trial of perioperative pembrolizumab (pembro) in early-stage NSCLC
- Phase 2, open-label study of ceritinib in patients (pts) with advanced non-lung solid tumors and hematological malignancies characterized by genetic abnormalities in anaplastic lymphoma kinase (ALK) using a flexible adaptive design: ASCEND-10
- Nilotinib vs. nilotinib plus interferon a induction and nilotinib or interferon a maintenance therapy for newly diagnosed BCR-ABL positive chronic myeloid leukemia patients in chronic phase: interim analysis of the TIGER (CML V) study
- Systemtherapie fortgeschrittener Weichteilsarkome
- Pazopanib vs pazopanib / gemcitabine in refractory soft tissue sarcoma: The AIO-STS-009-trial
- Treatment free remission in CML patients after first line nilotinib therapy
- Shades of insulinoma one century after first extensive evaluation by Wilder and colleagues; a figurative review between light and dark